LGL Partners’s iShares Biotechnology ETF IBB Stock Holding History

LGL Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,082	Closed	-$233K	–	110
2019 Q1	$233K	Hold	2,082	–	–	0.09%	99
2018 Q4	$201K	Sell	2,082 -1,200	-37%	-$127K	0.11%	48
2018 Q3	$400K	Hold	3,282	–	–	0.19%	42
2018 Q2	$360K	Hold	3,282	–	–	0.17%	46
2018 Q1	$350K	Hold	3,282	–	–	0.17%	50
2017 Q4	$350K	Buy	+3,282	New	+$351K	0.16%	50
2017 Q3	–	Sell	-3,282	Closed	-$339K	–	67
2017 Q2	$339K	Sell	3,282 -87	-3%	-$8.57K	0.18%	62
2017 Q1	$329K	Sell	3,369 -240	-7%	-$23K	0.17%	64
2016 Q4	$319K	Buy	3,609 +87	+2%	+$7.92K	0.18%	71
2016 Q3	$340K	Hold	3,522	–	–	0.18%	67
2016 Q2	$314K	Hold	3,522	–	–	0.17%	73
2016 Q1	$306K	Hold	3,522	–	–	0.16%	75
2015 Q4	$397K	Buy	+3,522	New	+$382K	0.22%	57

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LGL Partners's IBB Position: Q2 2019 in Review

LGL Partners sold out of iShares Biotechnology ETF (IBB) in Q2 2019, closing a stake of 2,082 shares — an estimated $233K sold.

LGL Partners first reported a position in IBB in Q4 2015 and held it in 13 quarters. The position peaked at $400K in Q3 2018. 646 funds tracked by Wall St. Rank hold IBB as of Q2 2019.

LGL Partners reported no remaining iShares Biotechnology ETF position as of Q2 2019 after selling out during the quarter.
LGL Partners sold 2,082 iShares Biotechnology ETF shares in Q2 2019, an estimated $233K.
LGL Partners first reported a position in iShares Biotechnology ETF in Q4 2015 and held it in 13 quarters.
LGL Partners's iShares Biotechnology ETF position peaked at $400K in Q3 2018.
646 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2019.

Based on LGL Partners's 13F filing for Q2 2019, filed 14 Aug 2019.